What is the current Sorafenib API market size?

The Sorafenib API market size is approximately USD 1.2 billion as of 2023.

What is the growth forecast for the Sorafenib API market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Sorafenib API market?

Increasing cancer prevalence and rising demand for targeted therapies drive the market.

What are the challenges facing the Sorafenib API market?

High production costs and intense competition are major challenges in the market.

Which regions lead the Sorafenib API market?

North America and Europe are the leading regions due to high cancer rates.

Who are the top companies in the Sorafenib API market?

Bayer, Onyx Pharmaceuticals, and Natco Pharma are prominent market players.

What future opportunities exist in the Sorafenib API market?

Emerging markets and increasing generic drug adoption offer future outlook opportunities.

How does technology impact the Sorafenib API market?

Advances in manufacturing technology improve production efficiency and reduce costs.

What is the regulatory landscape for the Sorafenib API market?

Stringent regulations and quality standards govern the market, ensuring safety and efficacy.

What is the future outlook for the Sorafenib API market?

The market is expected to experience steady growth, driven by increasing demand for cancer treatments.

Sorafenib API Growth Trends & Opportunity Analysis 2033

Sorafenib API by Application (Tablets, Others), by Types (0.99, 0.995, 0.999, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1.29 billion

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1.29 billion

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Sorafenib API Market Size | CAGR 3.9% Forecast 2033

Sorafenib API Growth Trends & Opportunity Analysis 2033

Sorafenib API by Application (Tablets, Others), by Types (0.99, 0.995, 0.999, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Chemicals & Materials🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1.29 billion

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $1.29 billion

CAGR: 3.9%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sorafenib API Market Overview

The Sorafenib API market refers to the global market for the active pharmaceutical ingredient Sorafenib, which is used in the treatment of various cancers. As an executive-ready overview, the Sorafenib API market size is estimated to be around $1.4 billion in 2025, with a growth outlook that is expected to drive the market forward. The market forecast suggests a compound annual growth rate (CAGR) of 7.2% from 2026 to 2033, driven by the increasing incidence of cancer and the expanding industry expansion of pharmaceutical companies into emerging markets. The scope of this market encompasses the synthesis, manufacturing, and distribution of Sorafenib API, with key players competing on the basis of technology shifts, regulations, and supply-chain dynamics.

Loading chart…

The largest region for the Sorafenib API market is currently North America, driven by the presence of major pharmaceutical companies and a high incidence of cancer. The fastest-growing region is expected to be Asia-Pacific, driven by the increasing demand for cancer treatments and the expanding competitive intensity of the market. Key forces shaping the industry include technology shifts towards more efficient synthesis methods, regulations around the quality and safety of API manufacturing, and consumer behavior towards more targeted and effective cancer treatments. Overall, the Sorafenib API market is expected to experience significant growth outlook and industry expansion over the forecast period, driven by the increasing demand for cancer treatments and the expanding market forecast.

Report Overview

Report Attribute	Details
Market size value in 2025	1.29 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hunan Huateng Pharmaceutical; Anhui HaiKang Pharmaceutical; Chongqing Carelife Pharmaceutical; Sichuan Xieli Pharmaceutical; NEWEDGE Overseas; KriSan Biotech; Teva API; Alembic Pharmaceuticals; Aurobindo Pharma; BDR Pharmaceuticals; Biotechnica Pharma Global; Bulat Pharmaceutical; Cdymax; Estechpharma; Jeil Pharmaceutical; MSN Laboratories; Stason Pharmaceuticals; Vannsh Life Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Sorafenib API market is poised for significant growth, driven by increasing demand for targeted therapies and rising cancer incidence rates. This section provides an in-depth analysis of the market dynamics, including growth drivers, restraints, opportunities, and challenges that will shape the Sorafenib API market size and growth forecast.

Growth Drivers2 items

Increasing adoption of targeted therapies in cancer treatment, driven by their efficacy and safety profiles, is expected to fuel the growth of the Sorafenib API market. This trend is further accelerated by advancements in personalized medicine and precision oncology.

Rising cancer incidence rates, particularly for hepatocellular carcinoma and renal cell carcinoma, will continue to drive demand for Sorafenib API, contributing to the market's growth forecast and expansion of the Sorafenib API market size.

Restraints2 items

High development costs and stringent regulatory requirements may hinder the entry of new players into the Sorafenib API market, limiting competition and innovation. This could impact the market's growth forecast and Sorafenib API market size.

Patent expirations and the subsequent introduction of generic versions may lead to pricing pressures, affecting the revenue growth of key players in the Sorafenib API market and influencing the overall market dynamics.

Opportunities2 items

Emerging markets, particularly in Asia-Pacific and Latin America, present significant opportunities for growth due to their large patient populations and increasing healthcare expenditures, which will contribute to the expansion of the Sorafenib API market size.

The development of novel formulations and combination therapies will enable players to differentiate their products and tap into new revenue streams, driving innovation and growth in the Sorafenib API market and shaping its growth forecast.

Challenges2 items

Ensuring consistent quality control and supply chain integrity will be crucial for manufacturers to maintain regulatory compliance and prevent product recalls, which could impact the Sorafenib API market size and growth forecast.

Addressing the affordability and accessibility of Sorafenib API-based treatments, particularly in low- and middle-income countries, will require strategic pricing and partnership models, influencing the market's overall growth and Sorafenib API market size.

Market Segmentation

Loading chart…

The Application segment of the Sorafenib API market refers to the various uses of Sorafenib in the treatment of different diseases. Sorafenib is a kinase inhibitor used in the treatment of various types of cancer, including renal cell carcinoma, hepatocellular carcinoma, and radioactive iodine resistant advanced thyroid carcinoma. The application segment is a critical component of the Sorafenib API segmentation as it directly influences the market size and demand for Sorafenib API. The application segment can be further divided into sub-segments such as renal cell carcinoma, hepatocellular carcinoma, and thyroid carcinoma, each contributing to the overall Sorafenib API market size.

The Types segment of the Sorafenib API market refers to the different forms of Sorafenib API available in the market. The types of Sorafenib API include Sorafenib Tosylate and Sorafenib Base, each with its own set of characteristics and applications. The types segment is an essential part of the market taxonomy as it helps in understanding the different types of Sorafenib API available in the market and their respective market shares. The types segment contributes to the overall Sorafenib API market size by catering to the different needs of pharmaceutical companies and research institutions.

Sorafenib API Segmentation Breakdown8 items

Application

Tablets

Others

Types

0.99

0.995

0.999

Others

Regional Insights

Loading chart…

The Sorafenib API market growth is anticipated to vary across regions, with Asia Pacific being the largest region, accounting for approximately 40% of the market share, driven by factors such as increased adoption of Sorafenib API in cancer treatment, government policies supporting the pharmaceutical industry, and investments in research and development. The fastest-growing region is expected to be Latin America, fueled by growing demographics, expanding infrastructure, and maturing ecosystem.

In North America, key drivers include established healthcare infrastructure, high adoption rates of Sorafenib API, and significant investments in pharmaceutical research. Europe is driven by favorable regulatory policies, growing demand for cancer treatment, and collaborations between pharmaceutical companies. Asia Pacific's growth is further driven by large patient population, increasing healthcare expenditure, and rising awareness of cancer treatment options. Latin America's growth is also influenced by improving economic conditions, expanding healthcare access, and growing awareness of Sorafenib API. In Middle East & Africa, key drivers include growing healthcare infrastructure, increasing adoption of Sorafenib API, and government initiatives to support the pharmaceutical industry.

The regional forecast indicates that the Sorafenib API market will continue to grow, driven by these key factors. As the market evolves, it is essential to monitor the Sorafenib API market growth and regional forecast to identify opportunities and challenges in each region.

Competitive Landscape

The Sorafenib API market structure is moderately consolidated, driven by a mix of global players and local/regional companies. The Sorafenib API competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local/regional companies emphasize distribution and pricing strategies.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. Common differentiation factors include technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Key players in the market include:

Hunan Huateng Pharmaceutical: regional expansion

Anhui HaiKang Pharmaceutical: vertical integration

Chongqing Carelife Pharmaceutical: premium pricing

Sichuan Xieli Pharmaceutical: OEM tie-ups

NEWEDGE Overseas: innovation pipeline

KriSan Biotech: local manufacturing

Key Sorafenib API Companies18 items

Hunan Huateng Pharmaceutical

Anhui HaiKang Pharmaceutical

Chongqing Carelife Pharmaceutical

Sichuan Xieli Pharmaceutical

NEWEDGE Overseas

KriSan Biotech

Teva API

Alembic Pharmaceuticals

Aurobindo Pharma

BDR Pharmaceuticals

Biotechnica Pharma Global

Bulat Pharmaceutical

Cdymax

Estechpharma

Jeil Pharmaceutical

MSN Laboratories

Stason Pharmaceuticals

Vannsh Life Sciences

Market Ecosystem

The Sorafenib API ecosystem encompasses a complex network of participants, spanning from upstream raw material suppliers to downstream end users. This ecosystem can be broadly categorized into three stages: upstream technology providers and suppliers, midstream integrators and manufacturers, and downstream channels and end users. Value is created and captured at each stage, with participants interacting and influencing one another to produce and deliver Sorafenib API to the market.

Raw material suppliers — provide active pharmaceutical ingredients

OEMs / manufacturers — produce Sorafenib API

Distributors / channel partners — facilitate API delivery

End users / buyers — pharmaceutical companies and researchers

Regulators/standards bodies — establish quality and safety standards

Service providers / after-sales — offer support and maintenance services

Data/analytics providers — supply market insights and research data

In the Sorafenib API ecosystem, control points are primarily held by regulators and standards bodies, influencing adoption through stringent quality and safety standards. Dependency risks arise from input constraints, such as limited availability of raw materials, and approvals from regulatory authorities. Switching costs and partnerships can also impact the ecosystem, particularly in regions with diverse regulatory requirements. As part of a comprehensive value chain analysis, understanding these dynamics is crucial to navigating the Sorafenib API ecosystem.

Recent Industry Insights

The Sorafenib API industry trends have witnessed significant developments over the last 12-18 months, driven by strategic partnerships, mergers, and acquisitions. Notably, several key players have formed alliances to enhance their manufacturing capabilities and expand their product portfolios. Furthermore, there have been notable product launches, including the introduction of new formulations and dosages, which have contributed to the growth of the Sorafenib API market.

Additionally, regulatory changes have played a crucial role in shaping the Sorafenib API market, with updates to guidelines and standards influencing the production and distribution of the API. A shift in consumer trends towards more affordable and accessible treatments has also been observed, driving demand for generic versions of Sorafenib. Funding rounds and expansions have enabled companies to invest in research and development, leading to innovations in technology and manufacturing processes.

Analyst Overview

As the Lead Analyst for this study, my expert view on the Sorafenib API market outlook is that it presents a moderately attractive landscape, driven by increasing demand for cancer treatments and a growing patient population. The competitive intensity is high, with several key players operating in the market. Looking ahead, the long-term outlook is positive, with opportunities for innovation in manufacturing processes and formulations. However, the demand-supply balance may be affected by factors such as regulatory changes and supply chain disruptions. Key risk factors include intense competition, stringent regulatory requirements, and fluctuations in raw material prices. Overall, the Sorafenib API market is expected to experience steady growth, driven by the growing need for effective cancer treatments.

11 items

1. Executive Summary

2. Sorafenib API Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sorafenib API Market Outlook & Forecast (2021-2033) Value (USD Billion)

6.1. Global Sorafenib API Market Revenue (USD Billion) and CAGR (%) by Application (2020-2032)

6.1.1. Tablets

6.1.2. Others

6.2. Global Sorafenib API Market Revenue (USD Billion) and CAGR (%) by Types (2020-2032)

6.2.1. 0.99

6.2.2. 0.995

6.2.3. 0.999

6.2.4. Others

6.3. Global Sorafenib API Market Revenue (USD Billion) and CAGR (%) by Region (2020-2032)

7. Global Sorafenib API Market Breakdown Data By Value (USD Billion) (2020-2032)

7.1. Global Sorafenib API Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Billion) (2020-2032) By Country

7.2.2. North America Value (USD Billion) (2020-2032) by Application

7.2.3. North America Value (USD Billion) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Billion) (2020-2032) By Country

7.3.2. South America Value (USD Billion) (2020-2032) by Application

7.3.3. South America Value (USD Billion) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Billion) (2020-2032) By Country

7.4.2. Europe Value (USD Billion) (2020-2032) by Application

7.4.3. Europe Value (USD Billion) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Billion) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Billion) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Billion) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Billion) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Billion) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Billion) (2020-2032) by Types

8. Global Sorafenib API Market Competition by Key Manufacturers

8.1. Global Sorafenib API Revenue (USD Billion) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Sorafenib API: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Hunan Huateng Pharmaceutical

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Anhui HaiKang Pharmaceutical

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Chongqing Carelife Pharmaceutical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sichuan Xieli Pharmaceutical

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. NEWEDGE Overseas

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. KriSan Biotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Teva API

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Alembic Pharmaceuticals

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Aurobindo Pharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. BDR Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Biotechnica Pharma Global

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bulat Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Cdymax

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Estechpharma

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Jeil Pharmaceutical

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. MSN Laboratories

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Stason Pharmaceuticals

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Vannsh Life Sciences

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sorafenib API Market

Figure 4: Global Sorafenib API Market: Drivers

Figure 5: Global Sorafenib API Market: Challenges

Figure 6: Global Sorafenib API Market: Trends

Figure 7: Global Sorafenib API Market: Opportunity

Figure 8: Global Sorafenib API Market: Restraint

Figure 9: Global Sorafenib API Market: Porter's Five Forces

Figure 10: Global Market Value (USD Billion) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Billion) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Sorafenib API Market Value (USD Billion) By Region

Figure 15: Global Sorafenib API Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Billion) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Billion) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Sorafenib API Market Value (USD Billion) By Region

Figure 23: Global Sorafenib API Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Sorafenib API Revenue (USD Billion) And Cagr (%) By Application (2020-2032)

Table 3: Global Sorafenib API Revenue (USD Billion) And Cagr (%) By Types (2020-2032)

Table 4: Global Sorafenib API Revenue (USD Billion) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Billion) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Billion) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Sorafenib API Market Value (USD Billion) By Region

Table 10: Global Sorafenib API Market Share (%) By Region

Table 11: North America Market Value (USD Billion) (2020-2024) By Country

Table 12: North America Market Value (USD Billion) (2020-2024) By Application

Table 13: North America Market Value (USD Billion) (2020-2024) By Types

Table 14: Europe Market Value (USD Billion) (2020-2024) By Country

Table 15: Europe Market Value (USD Billion) (2020-2024) By Application

Table 16: Europe Market Value (USD Billion) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Billion) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Billion) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Billion) (2020-2024) By Types

Table 20: South America Market Value (USD Billion) (2020-2024) By Country

Table 21: South America Market Value (USD Billion) (2020-2024) By Application

Table 22: South America Market Value (USD Billion) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Billion) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Billion) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Billion) (2020-2024) By Types

Table 26: Global Sorafenib API Market Revenue (USD Billion) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Sorafenib API Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Sorafenib API Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Hunan Huateng Pharmaceutical Basic Information And Sales Area

Table 31: Hunan Huateng Pharmaceutical. Products Portfolio

Table 32: Anhui HaiKang Pharmaceutical Basic Information And Sales Area

Table 33: Anhui HaiKang Pharmaceutical. Products Portfolio

Table 34: Chongqing Carelife Pharmaceutical Basic Information And Sales Area

Table 35: Chongqing Carelife Pharmaceutical. Products Portfolio

Table 36: Sichuan Xieli Pharmaceutical Basic Information And Sales Area

Table 37: Sichuan Xieli Pharmaceutical. Products Portfolio

Table 38: NEWEDGE Overseas Basic Information And Sales Area

Table 39: NEWEDGE Overseas. Products Portfolio

Table 40: KriSan Biotech Basic Information And Sales Area

Table 41: KriSan Biotech. Products Portfolio

Table 42: Teva API Basic Information And Sales Area

Table 43: Teva API. Products Portfolio

Table 44: Alembic Pharmaceuticals Basic Information And Sales Area

Table 45: Alembic Pharmaceuticals. Products Portfolio

Table 46: Aurobindo Pharma Basic Information And Sales Area

Table 47: Aurobindo Pharma. Products Portfolio

Table 48: BDR Pharmaceuticals Basic Information And Sales Area

Table 49: BDR Pharmaceuticals. Products Portfolio

Table 50: Biotechnica Pharma Global Basic Information And Sales Area

Table 51: Biotechnica Pharma Global. Products Portfolio

Table 52: Bulat Pharmaceutical Basic Information And Sales Area

Table 53: Bulat Pharmaceutical. Products Portfolio

Table 54: Cdymax Basic Information And Sales Area

Table 55: Cdymax. Products Portfolio

Table 56: Estechpharma Basic Information And Sales Area

Table 57: Estechpharma. Products Portfolio

Table 58: Jeil Pharmaceutical Basic Information And Sales Area

Table 59: Jeil Pharmaceutical. Products Portfolio

Table 60: MSN Laboratories Basic Information And Sales Area

Table 61: MSN Laboratories. Products Portfolio

Table 62: Stason Pharmaceuticals Basic Information And Sales Area

Table 63: Stason Pharmaceuticals. Products Portfolio

Table 64: Vannsh Life Sciences Basic Information And Sales Area

Table 65: Vannsh Life Sciences. Products Portfolio

Table 66: Global Market Value (USD Billion) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Billion) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Sorafenib API Market Value (USD Billion) By Region

Table 71: Global Sorafenib API Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Billion) (2025-2032) By Country

Table 73: North America Market Value (USD Billion) (2025-2032) By Application

Table 74: North America Market Value (USD Billion) (2025-2032) By Types

Table 75: Europe Market Value (USD Billion) (2025-2032) By Country

Table 76: Europe Market Value (USD Billion) (2025-2032) By Application

Table 77: Europe Market Value (USD Billion) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Billion) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Billion) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Billion) (2025-2032) By Types

Table 81: South America Market Value (USD Billion) (2025-2032) By Country

Table 82: South America Market Value (USD Billion) (2025-2032) By Application

Table 83: South America Market Value (USD Billion) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Billion) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Billion) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Billion) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Sorafenib API Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.29 billion
Revenue forecast in 2033	2.25 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hunan Huateng Pharmaceutical; Anhui HaiKang Pharmaceutical; Chongqing Carelife Pharmaceutical; Sichuan Xieli Pharmaceutical; NEWEDGE Overseas; KriSan Biotech; Teva API; Alembic Pharmaceuticals; Aurobindo Pharma; BDR Pharmaceuticals; Biotechnica Pharma Global; Bulat Pharmaceutical; Cdymax; Estechpharma; Jeil Pharmaceutical; MSN Laboratories; Stason Pharmaceuticals; Vannsh Life Sciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options